Lipfendra Cuts LDL Cholesterol 56%-59% as First Oral PCSK9 Pill

3 articles · Updated · Fox Carolina · Aug 4

Lipfendra, a once-daily tablet, lowered LDL cholesterol by 56% to 59% in clinical trials when added to standard statin therapy.
The drug is the first approved oral PCSK9 inhibitor, offering a pill alternative to injectable treatments that block cholesterol-producing proteins.
Dr. Nita Bijoor called the launch a clinical milestone as about 1 in 4 Americans has high LDL cholesterol and a heart attack occurs every 45 seconds.
Trial data showed the treatment was generally well tolerated, with diarrhea and dizziness reported as the most common mild side effects.

Sources

Fox Carolina2d ago

New Pill Lipfendra Lowers LDL Cholesterol by 56-59%, Offers Oral Alternative

linkedin2d ago

🚨Two FDA Approvals has changed the Future of the Lipid Management 🚨 🌐Dyslipidemia management is entering a new era with two important FDA approvals that target two major lipid challenges:… | Yasmin Hatem

Instagram2d ago

A first of its kind pill is helping patients lower their cholesterol by 60%. I interviewed @oakviewmedmd Dr. Nita Bijoor about why this is a breakthrough treatment.

Lipfendra slashes bad cholesterol by nearly 60%, but can this daily pill actually prevent heart attacks and strokes?

The new cholesterol pill replaces injections, but will its strict 30-minute daily fasting rule ruin real-world patient adherence?

Priced at $315 a month, will insurance companies easily approve this groundbreaking oral cholesterol drug for average patients?

Lipfendra (Enlicitide): The First Oral PCSK9 Inhibitor Slashes LDL-C by 56–60%—A Paradigm Shift in Cholesterol Management

Overview

Lipfendra (enlicitide) is the first once-daily oral PCSK9 inhibitor approved by the FDA to lower LDL cholesterol in adults with hypercholesterolemia. Developed as a room-temperature stable tablet, it eliminates the barriers of injectable therapies, such as needle anxiety and cold storage, making treatment more accessible and improving long-term adherence. Clinical trials showed Lipfendra reduces LDL-C by up to 59%. However, patients must follow a strict dosing protocol for best results. Priced at about half the cost of injectables, Lipfendra could expand access for millions, but insurers still require proof of statin failure and await long-term outcomes before full adoption.

...